槲皮素 Quercetin × 高血壓

結論:證據支持但有警示

Four independent meta-analyses (2016-2022, pooling 587-896 participants across up to 17 RCTs) consistently show quercetin produces a small but statistically significant reduction in systolic blood pressure of roughly 2-3 mmHg, with the effect concentrated at doses of 500 mg/day or higher and in pre/hypertensive populations.

B 🟡 B 初步證據 附警語發布 ⚠️ medium — moderate promotional content
⚠️ 標記 🇹🇼 台灣在地警示

Four independent meta-analyses (2016-2022, pooling 587-896 participants across up to 17 RCTs) consistently show quercetin produces a small but statistically significant reduction in systolic blood pressure of roughly 2-3 mmHg, with the effect concentrated at doses of 500 mg/day or higher and in pre/hypertensive populations. This consistency across multiple pooled analyses supports a real biological effect, but the magnitude is modest, the clinical meaning of a 2-3 mmHg surrogate change is uncertain (no hard cardiovascular outcome trials exist), funding sources are largely undisclosed, and there is meaningful between-study heterogeneity and inconsistent DBP results. Examine grades the primary Blood Pressure endpoint D (No effect), but this rests on only 3 studies (n=88) and is outweighed by the larger meta-analytic body of evidence. The totality therefore supports a Grade C: evidence exists and is reasonably consistent, but the effect is small and of uncertain clinical importance.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.61
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
76%
證據方向大致一致
證據層級
E2
多篇高品質統合分析(≥2 篇一致)

各層「支持此療效」的程度

分數越低=該層越不支持
L1 Examine國際基準
0.50
L11 AI 複核獨立判讀
0.50
L5 臨床機構權威立場
0.55
L3 機轉生理合理性
0.65
L2 PubMed原始文獻
0.70
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.61
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
PMID: 27405810 2016 統合分析 n = 587
結論:Quercetin significantly reduced SBP (WMD -3.04 mmHg, 95% CI -5.75 to -0.33, p=0.028) and DBP (WMD -2.63 mmHg, 95% CI -3.26 to -2.01, p<0.001); effect driven by doses ≥500 mg/day.
效應量:WMD SBP -3.04 mmHg; DBP -2.63 mmHg
前往 PubMed
Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: a systematic review and meta-analysis
PMID: 31940027 2020 統合分析 n = 896
結論:Quercetin significantly reduced SBP (WMD -3.09 mmHg, 95% CI -4.59 to -1.59, p=0.0001) and DBP (WMD -2.86 mmHg, 95% CI -5.09 to -0.63, p=0.01) across 17 RCTs.
效應量:WMD SBP -3.09 mmHg; DBP -2.86 mmHg
前往 PubMed
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
PMID: 35948195 2022 統合分析 n = 841
結論:Quercetin reduced SBP -2.38 mmHg (p=0.01) in mixed population and DBP -3.14 mmHg in (pre)hypertensive subgroup (p<0.00001); normotensive SBP reduction also significant (p<0.0001).
效應量:MD SBP -2.38 mmHg (mixed); DBP -3.14 mmHg (pre-hypertensive)
前往 PubMed
The Effects of Quercetin Supplementation on Blood Pressures and Endothelial Function Among Patients with Metabolic Syndrome and Related Disorders
PMID: 31092175 2019 統合分析
結論:Quercetin significantly reduced SBP (WMD -1.69 mmHg, 95% CI -3.22 to -0.17) but not DBP (WMD -3.14, 95% CI -8.24 to 1.95) in metabolic syndrome patients across 8 RCTs.
政府資助 效應量:WMD SBP -1.69 mmHg; DBP NS
前往 PubMed

L4a US FDA
謹慎
FDA has no questions; some uses may require a color additive listing 來源↗
L4b EU EFSA
反對
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
洋蔥萃取物原料係由洋蔥(Allium cepa)之鱗莖,經萃取製得。前點製得之洋蔥萃取物原料,其每日食用限量,以槲皮素(quercetin)計為1000毫克。 來源↗
L4e WHO
未表態
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
中性
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
未表態

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 中度
📍立場總覽

槲皮素用於高血壓在台灣社群(PTT/Dcard/Mobile01)幾乎沒有第一手降壓實測心得。可搜得的真實鄉民討論集中在 PTT allergy 看板(用於蕁麻疹/過敏、天然抗組織胺),如『現在則是吃槲皮素為主…發癢頻率沒這麼頻繁』,與高血壓無關;Biology 看板僅為學術代謝提問。提到『槲皮素降血壓』的內容幾乎全來自藥師部落格(微笑藥師/痞客邦)、營養新知與商業健康媒體(元氣網、foodnext),引用 730mg/28 天降收縮壓 7±2 mmHg 的小型研究,屬衛教/SEO 文而非社群實測。整體『槲皮素 x 高血壓』在地社群辯證訊號極低,未見鄉民分享個人血壓變化或品牌。

💬社群實感

無共識——台灣社群(PTT/Dcard/Mobile01)缺乏槲皮素用於高血壓的第一手降壓實測心得;少數真實鄉民經驗皆集中於過敏/蕁麻疹(PTT allergy 板),降血壓說法則主要來自藥師部落格與商業健康媒體的衛教文,非社群個人使用經驗

破解迷思 社群最常見的 3 個誤解
迷思把媒體/部落格引用的『每日 730mg、28 天降收縮壓 7±2 mmHg』小型試驗結果當成普遍可靠的降壓手段
事實該數字來自少量第一期高血壓受試者短期研究,個體差異大,多數統合分析需 >500mg/日且 >8 週方見微幅效果,不能取代降壓藥
迷思誤以為槲皮素可取代或自行『加強』降壓藥
事實槲皮素與 digoxin 等藥物有交互作用風險,正服降壓/心臟用藥者疊加應先諮詢醫師、藥師
迷思把『多吃洋蔥/蘋果攝取槲皮素就能明顯降血壓』當成等效於保健品劑量
事實天然食物中槲皮素含量與生體可用率有限,難達研究使用之高劑量,且效果證據仍以過敏抗發炎為主、降壓為次
🩹 社群通報的副作用
  • (衛教資料而非社群實測)高劑量可能出現噁心、頭痛、胃痛或四肢刺痛感
  • (衛教警示)肝腎功能不佳者、孕婦、哺乳期女性應避免;與 digoxin 併用有潛在風險

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

槲皮素膠囊400mg NT$750

代表來源 ↗
L10b · TFDA 法定身份 官方認定

洋蔥萃取物所含之槲皮素每日攝取量上限為1000mg

來源 ↗

  • DASH 飲食
  • 規律有氧運動
  • 降血壓藥物
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 4 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v24 engine_version: v1.0 claim_id: CLM-COND-hypertension-INT-quercetin-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-hypertension-INT-quercetin-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "槲皮素能改善高血壓",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 3,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟡 B 初步證據"
  }
}